On the other hand, inherited genetic variants were also consid-
ered to be involved in treatment outcomes, especially for adverse
drug reactions. For instance, some patients will suffer life-
threatening myelosuppression after mercaptopurine treatment
with standard dosage. Thanks to the well understanding of drug
metabolic pathway of mercaptopurine [18], TPMT enzyme activity
was noticed to be negatively related to the toxic content (i.e.,
metabolites of mercaptopurine) in plasma in Caucasians, and the
germline variants (e.g., TPMT*3C) can largely explain the loss of
function in TPMT, which were found through screening of the
Fig. 2Molecular subtypes of childhood ALL
392 Heng Xu and Yang Shu